Latest 8-K filings

Spyre Therapeutics announced positive 12-week induction topline data from Part A of its Phase 2 SKYLINE trial for SPY003, an anti-IL-23 therapy for ulcerative colitis.

1606 Corp. has executed a non-binding Letter of Intent with EthosEnergy O&M for operations and maintenance of its 55 MW Lufkin power facility, contingent on acquisition completion.

Arrive AI Inc. has posted an investor presentation to its website, attached as an exhibit to its Form 8-K filing.

Relmada Therapeutics, Inc. reported the end of Dr. Raj S. Pruth's employment as Chief Medical Officer, Urology, effective September 3, 2026.

Longevity Health Holdings announced a new securities purchase agreement with Puritan Partners LLC, securing up to $625,000 in gross proceeds through convertible notes.

Strategy Inc announced an increased digital credit securities repurchase program to $2.0 billion and provided an update on its bitcoin holdings and recent share repurchases.

Definium Therapeutics announced its DT120 ODT program for Major Depressive Disorder has received FDA Breakthrough Therapy designation, supported by positive Phase 3 results.

Sana Biotechnology announces significant progress in its Type 1 diabetes cell therapy (SC451) and in vivo CAR T cell programs, targeting IND filings and early clinical data in the near future.

Strive, Inc. announced a significant purchase of 1,375 bitcoin and an increase in cash and cash equivalents, alongside updates on its stock and preferred stock issuances.

GE Aerospace announced its agreement to acquire Consolidated Precision Products (CPP) for $11.75 billion to expand its mission-critical castings capacity and accelerate new engine technologies.

Group 1 Automotive announced its intention to offer $1.25 billion in senior unsecured notes to fund the acquisition of Hennessy Automobile Companies and related assets.

IonQ announced an increased full-year 2026 financial outlook, projecting revenue between $450 million and $460 million, incorporating contributions from the recently acquired SkyWater Technology.

Pyxis Oncology has appointed Thomas Civik as its permanent Chief Executive Officer and Chairman of the Board, effective September 4, 2026, reinforcing its focus on advancing its MICVO program.

Nabors Industries published an investor presentation on September 8, 2026, detailing advancements in technology-led growth, balance sheet strengthening, and international expansion.

Philip Morris International announced it is raising its 2026 full-year reported diluted EPS forecast to $7.28-$7.43, driven by currency adjustments, while maintaining its adjusted diluted EPS guidance.

enGene Therapeutics announced third quarter 2026 financial results, highlighting progress in its investigational therapy detalimogene for NMIBC and a strong cash position.

United Community Banks announces completion of strategic initiatives including a balance sheet repositioning and sale of Navitas, aiming to reduce interest rate risk and enhance future earnings.

Soluna Holdings announced the completion of its 83 MW Project Kati 1 and conditional Base Load classification for its full 166 MW campus in ERCOT, boosting total operating capacity to 206 MW.

Rigetti Computing has entered into a material definitive agreement with the U.S. Department of Commerce for up to $100 million to accelerate superconducting quantum computing research and development.

X4 Pharmaceuticals announced a positive outcome from its FDA Type C meeting, securing agreement on a reduced sample size for its Phase 3 chronic neutropenia trial, potentially accelerating timelines.

Tonix Pharmaceuticals announced the immediate promotion of Thomas Englese to Chief Commercial Officer, effective September 8, 2026, recognizing his leadership in the commercialization of TONMYA.

ABM Industries announced record-breaking fiscal third quarter 2026 results, with revenue climbing 4.2% to $2.3 billion, alongside a raised outlook for full-year adjusted EPS and free cash flow.

Kiora Pharmaceuticals announced the appointment of Keith Lane as Executive Vice President of Clinical Development and Regulatory Affairs, bringing extensive ophthalmology trial experience.

Kura Oncology, Inc. announced the appointment of Jennifer Fulk as Chief Financial Officer, effective September 8, 2026, detailing her compensation and equity awards.

OneWater Marine Inc. announced the resignation of director Jeffery B. Lamkin, effective September 3, 2026, leading to a reduction in the Board's size.

Willis Lease Finance Corporation presented its integrated aviation platform strategy, emphasizing expanded services and institutional capital deployment at the Deutsche Bank Aviation Forum.

VisionWave Holdings, Inc. has released an updated corporate overview presentation, incorporating information for investor meetings and public access.

Monte Rosa Therapeutics announced a $50 million milestone payment from Novartis as the Phase 2 clinical study for MRT-6160 (DDY391) in Sjögren's disease has been initiated.

United Natural Foods, Inc. announced robust fourth quarter and full fiscal year 2026 financial results, showcasing significant Adjusted EBITDA and Free Cash Flow growth, and provided an optimistic outlook for fiscal year 2027.

D-Wave Quantum Inc. has entered into a material definitive agreement with the U.S. Department of Commerce for up to $100 million in funding to advance quantum computing research and development.